Skip to content
About
Pipeline
MB-105
News & Publications
Menu
About
Pipeline
MB-105
News & Publications
Contact
Contact
About
Pipeline
MB-105
News & Publications
Menu
About
Pipeline
MB-105
News & Publications
Anti-tumor Efficacy and Safety of Unedited Autologous CD5.CAR T cells in Relapsed/Refractory Mature T-cell Lymphomas
April 3, 2024
4:24 pm
Prev
Previous
Enhanced anti-tumor activity of CD5 CAR T cells manufactured with tyrosine kinase inhibitors in patients with relapsed/refractory T-ALL
Next
Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicity
Next
Scroll Up
